Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Hematotoxic Effects of Particulate Exposure
This study has been completed.
Sponsored by: National Institute of Environmental Health Sciences (NIEHS)
Information provided by: National Institute of Environmental Health Sciences (NIEHS)
ClinicalTrials.gov Identifier: NCT00015483
  Purpose

Hematotoxicity is caused by a number of agents such as a benzene by-product called hydroquinone and the antitumor agent doxorubicin. This is a basic research study, conducted using normal human donors, of mechanisms involved in hematotoxicity and of the protective response of human hematopoietic progenitor cells to hematotoxic agents. Tumor necrosis factor exposure protects these cells from a subsequent exposure to hematotoxic agents. The alteration of gene expression in these cells caused by tumor necrosis factor is being studied. Additionally, the tumor necrosis factor-induced biochemical pathways involved in protection of human hematopoietic progenitor cells will be studied.


Condition
Cancer

MedlinePlus related topics: Cancer
Drug Information available for: Doxorubicin Doxorubicin hydrochloride
U.S. FDA Resources
Study Type: Observational
Study Design: Random Sample
Official Title: Hematotoxic Effects of Benzene and Doxorubicin
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • healthy
  • nonsmoking
  • no history of hematologic disorder
  • not pregnant
  • no medications which suppress hematopoiesis
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Study ID Numbers: 5020-CP-001
Study First Received: April 20, 2001
Last Updated: September 1, 2006
ClinicalTrials.gov Identifier: NCT00015483  
Health Authority: United States: Federal Government

Keywords provided by National Institute of Environmental Health Sciences (NIEHS):
Hematotoxicity
Benzene
Bone Marrow

Study placed in the following topic categories:
Doxorubicin

ClinicalTrials.gov processed this record on January 16, 2009